Winthrop KL, Tanaka Y, Takeuchi T, Kivitz A, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis 2021 Nov 5. pii: annrheumdis-2021-221051.
PMID: 34740884